BOPA (The British Oncology Pharmacy Association)
BOPA is the UK professional membership association for oncology pharmacy, serving pharmacists and pharmacy technicians across the NHS through the SACT Verification Passport, e-learning, drug monographs, HTA CPD courses, and an annual conference.
- Company typePrivate
- Founded-
- HeadquartersUnited Kingdom, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BOPA (The British Oncology Pharmacy Association) does
The British Oncology Pharmacy Association (BOPA) is a registered charity (CIO, Charity No. 1065026) and the dedicated professional membership body for oncology pharmacy professionals in the United Kingdom. Its mission is to standardise competency, advance education, and provide a community for pharmacists and pharmacy technicians working in cancer services, primarily across the NHS. The organisation transitioned to CIO governance following an October 2024 membership vote and is led by an elected Executive Committee headed by Chair Shereen Nabhani-Gebara, with subcommittees, Cancer Advisory Groups, International Groups, and a Fellows programme supporting its activities.
BOPA's core product is the Digital SACT Verification Passport, described as a leading global pharmacy competency training programme for verification of Systemic Anti-Cancer Therapy, rolled out across all four UK devolved nations and provided free to paid members and free associates. Supporting products include an eLearning course catalogue with stop-and-continue modules, BOPA/IOCN drug monographs for immune-related adverse events from checkpoint inhibitors, a Continuing Professional Development course on Health Technology Assessment developed with the University of York and NICE and endorsed by HTAi, a resource library, member forums, the 'Let's Talk About SACT' podcast, and the 29th Annual Conference scheduled for October 2026 at ICC London Olympia. Technology infrastructure is a standard digital membership portal integrating Google Analytics, Vimeo, and SimpleCast, with no disclosed AI/ML capability.
The revenue model rests on three streams: (1) annual individual membership at £65, including passport and e-learning access; (2) one-time conference registration fees at £300 for early-bird members; and (3) corporate membership with separate terms providing access and visibility for pharmaceutical and healthcare companies. Additional income includes the Gilead Sciences-funded Training and Development Grant, awarding 16 funded conference places annually. BOPA reaches members through LinkedIn, Instagram, Facebook, Bluesky, WhatsApp, email newsletters, podcasts, and webinars, with the annual conference as the flagship in-person engagement event.
BOPA (The British Oncology Pharmacy Association) firmographics
Firmographics- Name
- BOPA (The British Oncology Pharmacy Association)
- Legal name
- The British Oncology Pharmacy Association
- Website
- https://bopa.org.uk
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BOPA is the UK professional membership association for oncology pharmacy, serving pharmacists and pharmacy technicians across the NHS through the SACT Verification Passport, e-learning, drug monographs, HTA CPD courses, and an annual conference.
- Ownership category
- akta.pro rank
Where BOPA (The British Oncology Pharmacy Association) is headquartered
LocationHeadquarters
- HQ city
- United Kingdom
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
BOPA (The British Oncology Pharmacy Association) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Annual Membership Fees: Annual membership fee of £65 provides access to the SACT Verification Passport (free for paid members), e-learning modules, resources, forums, and reduced conference fees.
- Conference Fees: Revenue generated from annual conference registration. BOPA members pay £300 (including VAT) when booked by the early deadline, with non-member pricing higher.
- Corporate Membership: Corporate membership available for companies, with separate terms and conditions, providing access and visibility to the oncology pharmacy professional community.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Standard Annual Membership |
| One time/ perpetual license | One time/ perpetual license | Conference Registration (Member Rate) |
| Other | One time/ perpetual license | Training and Development Grant (Gilead-funded) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
BOPA (The British Oncology Pharmacy Association) product offering
Product offeringCore offering
BOPA is a UK professional association that supports oncology pharmacists and pharmacy technicians through an annual membership delivering access to the Digital SACT Verification Passport, CPD-accredited eLearning courses, Health Technology Assessment training, the BOPA/IOCN Drug Monographs for irAEs, member forums, a podcast and resources. It also runs a paid Annual Conference and offers a Corporate Membership scheme for NHS organisations and industry partners, while distributing sponsored grants such as the Gilead-funded Training and Development Grant.
Product overview
BOPA offers a portfolio of professional development and education products for oncology pharmacy professionals in the UK. The core offering is the BOPA Digital SACT Verification Passport, a competency training programme for verification of Systemic Anti-Cancer Therapy. Supporting this are eLearning courses for field-specific certification and CPD, the BOPA/IOCN Drug Monographs for immune-related adverse events, and a Health Technology Assessment CPD course developed with the University of York and NICE. The association also provides community engagement through forums, hosts an annual conference, produces a podcast series, and offers training grants. The products serve the 3,000+ professionals working in NHS pharmacy services across the UK.
Differentiator
Problem solved
Functional benefit
Products and services
- Annual Individual Membership Annual subscription product for individual oncology pharmacists and pharmacy technicians that unlocks the BOPA Digital SACT Verification Passport, CPD-accredited eLearning courses, Health Technology Assessment (HTA) CPD course, BOPA/IOCN Drug Monographs for irAEs, member forums, podcasts and online resources. Priced at approximately £65 (early bird) per year for a 12-month period.
- Corporate Membership Bespoke corporate membership scheme for organisations, including NHS pharmacy services and pharmaceutical industry partners, providing dedicated contact with BOPA and engagement with the association's oncology pharmacy network.
- Annual Conference Registration Paid registration for BOPA's flagship Annual Conference, priced separately from membership at approximately £300 for members, with tiered pricing for non-members. The conference serves as the association's main in-person networking and education event for oncology pharmacy professionals.
Quantifiable outcome
- The BOPA Digital SACT Verification Passport has been rolled out successfully across all four devolved nations of the UK and is described as a 'leading global pharmacy competency training programme.'
- +1 more outcomes
Companies that use BOPA (The British Oncology Pharmacy Association)
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
BOPA (The British Oncology Pharmacy Association) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature3 records
BOPA (The British Oncology Pharmacy Association) partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- Gilead SciencescoreBOPA is collaborating with Gilead Sciences on the Training and Development Grant, offering 16 funded places to the BOPA 2026 Conference. This includes 5 places for Pharmacy Technicians, 5 for New to Cancer Pharmacy Professionals (<2 years' experience), and 6 Standard Places. Gilead has had no input into the selection of recipients.
- IOCN (International Oncology Cancer Network)coreBOPA collaborated with IOCN to produce drug monographs for immune-related adverse events (irAEs) related to checkpoint inhibitor use. These monographs support all healthcare professionals in the use of these drugs across solid tumour sites.
- University of YorksupportingThe University of York provided expertise to support the development of BOPA's Health Technology Assessment (HTA) Continuing Professional Development course.
- NICE (National Institute for Health and Care Excellence)supportingNICE provided expertise to support the development of BOPA's Health Technology Assessment (HTA) Continuing Professional Development course.
- Health Technology Assessment International (HTAi)supportingHTAi has endorsed BOPA's Health Technology Assessment (HTA) CPD course. This endorsement provides additional credibility to the course as part of BOPA's passport scheme of core training accreditation.
- BSH Supportive Care Specialist Interest GroupsupportingBOPA promotes webinars from the British Society for Haematology (BSH) Supportive Care Specialist Interest Group, including a webinar on Consensus methods, which can be applied to co-production of new approaches to care, services or guidelines.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
BOPA (The British Oncology Pharmacy Association) competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights6 records
Customer concentration
BOPA (The British Oncology Pharmacy Association) social profiles
Digital presenceBOPA (The British Oncology Pharmacy Association) financial estimates
Financial estimateRevenue estimate
Valuation estimate
BOPA (The British Oncology Pharmacy Association) leadership team
Management profileNumber of profiles
Profiles3 records
BOPA (The British Oncology Pharmacy Association) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BOPA (The British Oncology Pharmacy Association) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BOPA (The British Oncology Pharmacy Association)
What does BOPA (The British Oncology Pharmacy Association) do?
BOPA is a UK professional association that supports oncology pharmacists and pharmacy technicians through an annual membership delivering access to the Digital SACT Verification Passport, CPD-accredited eLearning courses, Health Technology Assessment training, the BOPA/IOCN Drug Monographs for irAEs, member forums, a podcast and resources. It also runs a paid Annual Conference and offers a Corporate Membership scheme for NHS organisations and industry partners, while distributing sponsored grants such as the Gilead-funded Training and Development Grant.
Is BOPA (The British Oncology Pharmacy Association) a public or private company?
BOPA (The British Oncology Pharmacy Association) is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was BOPA (The British Oncology Pharmacy Association) founded?
BOPA (The British Oncology Pharmacy Association) was founded in -1. It employs 11 to 50 people.
Where is BOPA (The British Oncology Pharmacy Association) based?
BOPA (The British Oncology Pharmacy Association) is headquartered in United Kingdom, United Kingdom, in the Europe region.
How does BOPA (The British Oncology Pharmacy Association) make money?
Three revenue lines are on record. Annual Membership Fees are the primary driver. The others are conference Fees and corporate Membership.
Does BOPA (The British Oncology Pharmacy Association) have an API?
No public API is recorded for BOPA (The British Oncology Pharmacy Association).